Potassium
As of the edition of 20 October 2026, Potassium is a small molecule: marketed, first approved in 1951 (CA).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2018
- Kind
- Small molecule
- Brand name
- Lactated Ringer's In Plastic Container
- First approved
- 31 December 1951 (CA)
- Approvals on record
- 429 in 4 regions
- Holder of the most recent approval
- Clinigen; 45 holders in all
- Registered trials
- 6, 2 stopped early
- Disease areas
- Heart and blood vessels; Inherited and neonatal; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 1 | 0 |
| Phase 1 | 1 | 0 | 0 | 1 |
| Phase 2 | 2 | 1 | 0 | 1 |
| Phase 3 | 2 | 2 | 0 | 0 |
| All trials | 6 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Pfizer | Applicant, Acquired holder and Later holder | 1951 to now |
| Baxter Healthcare | Later holder | 1957 to now |
| Alcon | Later holder | 1980 to now |
| Hikma Pharmaceuticals | Later holder | 1982 to now |
| Anbex | Later holder | 1982 to now |
| Upsher-Smith | Later holder | 1986 to now |
| Merck & Co. | Later holder | 1986 to now |
| B. Braun Medical | Later holder | 1992 to now |
| Johnson & Johnson | Later holder | 1994 to now |
| Bristol Myers Squibb | Acquired holder | 2003 to now |
| Kv Pharmaceutical | Acquired holder | 2003 to now |
| Mission Pharmacal | Acquired holder | 2003 to now |
| Savage | Acquired holder | 2003 to now |
| Nesher Pharmaceuticals | Acquired holder | 2011 to now |
| AbbVie | Acquired holder | 2012 to now |
| Abbott | Later holder | 2013 to now |
| Ut Southwestern Medctr | Acquired holder | 2014 to now |
| Viatris | Acquired holder | 2016 to now |
| Genus Life Sciences | Acquired holder | 2017 to now |
| EA Pharma | Applicant | 2018 to now |
| Nihon Pharmaceutical | Later holder | 2021 to now |
| Genus Lifesciences | Acquired holder | 2024 to now |
| Otsuka | Acquired holder | 2025 to now |
| Clinigen | Later holder | 2025 to now |
| Eli Lilly | Applicant | |
| Novartis | Later holder |